Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inbeom Lee

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Information and Inference : a Journal of the IMA|March 14, 2025
Optimal variable clustering for high-dimensional matrix valued dataInbeom Lee, Siyi Deng, Yang Ning
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 21, 2025
Development of recombinant Mesozumab-CPTin that dual-targets mesothelin and CP2c for anticancer therapyBoram Kim, Kyu Tae Byun, Junmin Cho, et al.
Biomolecules|October 28, 2023
Development of an Anti-HER2 Single-Chain Variable Antibody Fragment Construct for High-Yield Soluble Expression in <i>Escherichia coli</i> and One-Step Chromatographic PurificationKyu Tae Byun, Boram Kim, Junmin Cho, et al.
Biomaterials Advances|February 21, 2026
Development of a HER1/CP2c dual-targeting biopharmaceutical for HER1-overexpressing head and neck cancerKyu Tae Byun, Junmin Cho, Boram Kim, et al.
Advanced Healthcare Materials|December 12, 2025
Preclinical Proof of Concept for the Single-Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular OncoproteinKyu Tae Byun, Boram Kim, Inbeom Lee, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Information and Inference : a Journal of the IMA|March 14, 2025
Optimal variable clustering for high-dimensional matrix valued dataInbeom Lee, Siyi Deng, Yang Ning
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 21, 2025
Development of recombinant Mesozumab-CPTin that dual-targets mesothelin and CP2c for anticancer therapyBoram Kim, Kyu Tae Byun, Junmin Cho, et al.
Biomolecules|October 28, 2023
Development of an Anti-HER2 Single-Chain Variable Antibody Fragment Construct for High-Yield Soluble Expression in <i>Escherichia coli</i> and One-Step Chromatographic PurificationKyu Tae Byun, Boram Kim, Junmin Cho, et al.
Biomaterials Advances|February 21, 2026
Development of a HER1/CP2c dual-targeting biopharmaceutical for HER1-overexpressing head and neck cancerKyu Tae Byun, Junmin Cho, Boram Kim, et al.
Advanced Healthcare Materials|December 12, 2025
Preclinical Proof of Concept for the Single-Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular OncoproteinKyu Tae Byun, Boram Kim, Inbeom Lee, et al.
Pageof 1